Stifel lowered the firm’s price target on Nurix Therapeutics (NRIX) to $33 from $35 and keeps a Buy rating on the shares after the company recently reported Q3 results and updated on bexobrutideg registrational plans. The firm’s updated estimates primarily reflect “modestly-higher” FY25 and beyond operating expenses, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- 3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts
- Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer
- Nurix Therapeutics price target lowered to $32 from $35 at Piper Sandler
- Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Closing Bell Movers: Levi Strauss down 8% after results